Multiple Myeloma Patients At High Risk For Deadly Infections

As if patients with multiple myeloma didn't have enough to worry about, an abstract presented at the recent American Society of Hematology meeting suggests that, following diagnosis, their cancer is not presenting the greatest threat to their lives.

Instead, Swedish researchers are reporting that more than one of every five patients with multiple myeloma dies within a year of being diagnosed on account of infection.

Specifically, multiple myeloma patients are at a very high risk of developing both viral and bacterial infections during the first year following their diagnosis and dying from the infection—a risk about 12 times higher compared to a control group. And that's just in the first year. Overall, these patients face a sevenfold risk compared to a control group.

Said Cecilie Blimark MD, of Gothenberg's Sahlgrenska University Hospital:

"We found that bacterial and viral infections represent a major threat to myeloma patients. We found the risk of specific infections, such as pneumonia and septicemia, to be more than 10 times higher in patients than in controls during the first year after diagnosis of multiple myeloma."

Researchers used data compiled from more than 9,600 multiple myeloma patients found in the Swedish national cancer registry between 1988 and 2004. They were compared to a control group of almost 38,000 people matched in age and sex.

The most frequent infection types included septicemia and meningitis.

Unfortunately, the investigators have no direct explanation for why the infection rate is so high and so deadly among this patient population.

Source: ASH 2012

More Articles

More Articles

Amazon.com is pleased to have the Lymphoma Information Network in the family of Amazon.com associates. We've agreed to ship items...

The question ought to be what are myelodysplastic syndromes (MDS), since this is a group of similar blood and bone marrow diseases that...

Merkel Cell Carcinoma (MCC) is a very rare and aggressive skin cancer that usually develops when a person is in his or her 70s. It is...

Radiation Therapy Topics

...

At some point, the Seattle biotech company Cell Therapeutics Inc (CTI) should earn an entry in the Guinness Book of World Records for utter and...

Site Beginnings

This site was started as Lymphoma Resource Page(s) in 1994. The site was designed to collect lymphoma...

Three papers appearing in the journal Blood and pointing towards a regulator-suppressor pill could offer hope to blood cancer...

The US Food and Drug Administration (FDA) has granted a third so-called Breakthrough Therapy Designation for the investigational oral...

The US Food and Drug Administration today has approved an expanded use of Imbruvica (ibrutinib) in patients with...

The U.S. Food and Drug Administration has announced that it has granted "Breakthrough Therapy Designation" for the investigational agent...

According to a new study published in the Proceedings of the National Academy of Sciences, a team from the University of California, San...

Pharmacyclics has announced that the company has submitted a New Drug Application (NDA) to the US Food and Drug Administration (FDA) for...

New research suggests that frontline radioimmunotherapy...

Gilead Sciences has announced results of the company's Phase II study of its investigational compound idelalisib, an oral inhibitor of...

Sitemap